We analyzed the expression levels of LILRB2, TLR2, NCF2, and S100A9 in AMI samples (blood samples on the first day of myocardial infarction) and stable coronary artery disease (CAD) controls (Figure 4). This evidence concerns the gene LILRB2 and coronary artery disorder.